EZH2 and cancer: In our in vivo model, EZH2 modulation using CRISPR/Ca9 greatly reduced tumor growth and Ki-67-positive cells and exhibited a significant reduction in the number of cancer-associated fibroblasts (CAFs) in tumors derived from SW1736-edited cells compared to control.